CANbridge Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

CANbridge Pharmaceuticals ha aumentado sus beneficios a una tasa media anual de 11.1%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento anual de 11.7%. Los ingresos han ido creciendo a una tasa media de 58.8% al año.

Información clave

11.1%

Tasa de crecimiento de los beneficios

53.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	11.0%
Tasa de crecimiento de los ingresos	58.8%
Rentabilidad financiera	n/a
Margen neto	-368.3%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Apr 23

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

May 05

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero CANbridge Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

SEHK:1228 Ingresos, gastos y beneficios (CNY Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	103	-379	174	257
30 Sep 23	95	-416	179	277
30 Jun 23	87	-453	184	296
31 Mar 23	83	-468	190	304
31 Dec 22	79	-483	196	311
30 Sep 22	66	-733	221	311
30 Jun 22	54	-982	247	311
31 Mar 22	42	-1,089	255	440
31 Dec 21	31	-1,077	246	428
30 Sep 21	27	-1,055	213	388
30 Jun 21	22	-1,034	181	349
31 Mar 21	18	-828	149	168
31 Dec 20	12	-846	129	110
31 Dec 19	1	-218	83	55

Ingresos de calidad: 1228 actualmente no es rentable.

Margen de beneficios creciente: 1228 actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 1228 no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 11.1% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de 1228 en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: 1228 no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (22.1%).

Rentabilidad financiera

Alta ROE: El pasivo de 1228 supera su activo, por lo que es difícil calcular su rentabilidad financiera.

CANbridge Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CANbridge Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: CN¥0.51 loss per share (vs CN¥0.59 loss in 1H 2022)

CANbridge Pharmaceuticals Inc. to Report First Half, 2023 Results on Aug 30, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

First half 2022 earnings released: CN¥0.59 loss per share (vs CN¥46.79 loss in 1H 2021)

Recent updates

Consensus EPS estimates fall by 23%

Price target decreased by 21% to HK$7.00

Consensus EPS estimates upgraded to CN¥0.59 loss

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CANbridge Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee

CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress

CANbridge Announces NDA Acceptance of CAN108 (???®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration

Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China

Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Algs)

First half 2023 earnings released: CN¥0.51 loss per share (vs CN¥0.59 loss in 1H 2022)

CANbridge Pharmaceuticals Inc. to Report First Half, 2023 Results on Aug 30, 2023

Price target decreased by 82% to HK$1.70

Consensus revenue estimates decrease by 22%, EPS upgraded

New minor risk - Share price stability

CANbridge Pharmaceuticals Inc. Announces Preliminary Clinical Data of Phase 1B Study of Omoprubart (CAN106) in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Consensus EPS estimates upgraded to CN¥1.05 loss

CANbridge Pharmaceuticals, Inc. Announces Marketing Approval of CAN108 (LIVMARLI) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

CANbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in China Region of the Global LIVMARLI(R) (CAN108) EMBARK Phase 2 Study in Biliary Atresia

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China

High number of new and inexperienced directors

First half 2022 earnings released: CN¥0.59 loss per share (vs CN¥46.79 loss in 1H 2021)

CANbridge Pharmaceuticals Inc. to Report First Half, 2022 Results on Aug 24, 2022

Canbridge Pharmaceuticals Inc. Announces First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China

CANbridge Pharmaceuticals Inc. Forms Scientific Advisory Board

Canbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Announces Results from its CAN106 Phase 1 Trial

CANbridge Pharmaceuticals Inc. Appoints Pauline Li as Senior Vice President of Clinical Development and Operations

High number of new and inexperienced directors

CANbridge Pharmaceuticals Inc. Announces Executive Changes

CANbridge Pharmaceuticals Inc. Announces First Patient Has Been Dosed in the Can106 Phase 1B/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria in China

Canbridge Pharmaceuticals Inc. Announces Approval of Can108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone

CANbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Reports Positive Top-Line Can106 Phase 1 Data

CANbridge Pharmaceuticals CAN108 New Drug Application (NDA) for Alagille Syndrome Accepted by China’s National Medical Products Administration

CANbridge Pharmaceuticals Inc. has completed an IPO in the amount of HKD 685.13718 million.

Less than half of directors are independent

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta